For instance, CD95 loss limits tumour incidence in KRASG12D+/−/PTEN−/−-driven ovarian cancer and diethlynitrosamine (DEN)-induced hepatocellular carcinoma (HCC) models [114]. Here, FAS is linked to hepatocellular carcinoma.